OAM
TCRT icon

Oxford Asset Management’s Alaunos Therapeutics TCRT Stock Holding History

Oxford Asset Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-152
Closed -$133K – 1945
2019
Q2 		$133K Buy
+152
New +$105K ﹤0.01% 1596
2015
Q2 		– Sell
-718
Closed -$1.16M – 737
2015
Q1 		$1.16M Buy
+718
New +$1.06M 0.03% 436
2014
Q2 		– Sell
-687
Closed -$472K – 772
2014
Q1 		$472K Buy
+687
New +$460K 0.01% 521

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Oxford Asset Management's TCRT Position: Q3 2019 in Review

Oxford Asset Management sold out of Alaunos Therapeutics (TCRT) in Q3 2019, closing a stake of 152 shares — an estimated $133K sold.

Oxford Asset Management first reported a position in TCRT in Q1 2014 and held it in 3 quarters. The position peaked at $1.16M in Q1 2015. 142 funds tracked by Wall St. Rank hold TCRT as of Q3 2019.

  • Oxford Asset Management reported no remaining Alaunos Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Oxford Asset Management sold 152 Alaunos Therapeutics shares in Q3 2019, an estimated $133K.
  • Oxford Asset Management first reported a position in Alaunos Therapeutics in Q1 2014 and held it in 3 quarters.
  • Oxford Asset Management's Alaunos Therapeutics position peaked at $1.16M in Q1 2015.
  • 142 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2019.

Based on Oxford Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.